Pirmitegravir
Pirmitegravir is a potent and first-in-class inhibitor of allosteric integrase (ALLINI) that targets LEDGF/p75 binding site. Pirmitegravir displays picomolar IC50 in human PBMCs with a >24,000 therapeutic index against HIV-1. Pirmitegravir harbors outstanding anti-virus and safety properties[1].
Product Specifications
CAS Number
[2245231-10-9]
Product Name Alternative
STP0404
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
HIV; HIV Integrase
Type
Reference compound
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/pirmitegravir.html
Purity
99.76
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C([C@H](C1=C(N=C(C2=C1C3=CC=C(C=C3)Cl)N(C(C)=C2C)CC4=CN(N=C4)C)C)OC(C)(C)C)O
Molecular Formula
C27H31ClN4O3
Molecular Weight
495.01
Precautions
H302, H315, H319
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Lentiviral human BTF3 shRNA (UAS) - Lentiviral human BTF3 shRNA (UAS, RFP) (100)
OPRL1 (Nociceptin Receptor, Kappa-Type 3 Opioid Receptor, KOR-3, Orphanin FQ Receptor, OPRL1, OOR, ORL1) discontinued
OPRL1 (Nociceptin Receptor, Kappa-Type 3 Opioid Receptor, KOR-3, Orphanin FQ Receptor, OPRL1, OOR, ORL1) discontinued